Inventage Lab

Inventage Lab EBITDA per Share

The EBITDA per Share of Inventage Lab (389470.KQ) as of Oct 21, 2026 is -2,137.56 KRW. In the previous year, EBITDA per Share was -1,706.45 KRW — a change of 25.26% (lower).

EBITDA per Share

-2,137.56KRW

YoY

25.26%

Last updated:

EBITDA per Share of Inventage Lab is 2025 -2,137.56 KRW. EBITDA per Share of Inventage Lab was 2024 -1,706.45 KRW. It decreases by 25.26% lower compared to the previous year.

The Inventage Lab EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2019
-521.17 KRW
Jan 1, 2020
-622.47 KRW
Jan 1, 2021
-1,115.24 KRW
Jan 1, 2022
-1,251.33 KRW
Jan 1, 2023
-3,139.99 KRW
Jan 1, 2024
-1,706.45 KRW
Jan 1, 2025
-2,137.56 KRW
The Inventage Lab EBITDA per Share history
YEAREBITDA per ShareYoY
-2,137.56KRW+25.26%
-1,706.45KRW-45.65%
-3,139.99KRW+150.93%
-1,251.33KRW+12.20%
-1,115.24KRW+79.16%
-622.47KRW+19.44%
-521.17KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Inventage Lab Stock analysis

What does Inventage Lab do? Inventage Lab, Inc. generates revenue through the research, manufacture, and sale of human medicines targeting male pattern baldness, dementia, and prostate cancer, as well as veterinary medicines including combination drugs and chemical castration agents. The company leverages its proprietary platforms for long-acting injections and genetic material drug delivery to develop and scale production of these products. Its human medicine segment focuses on therapeutic areas with significant market demand, while veterinary medicines serve agricultural and companion animal markets. The firm's business model centers on proprietary technology platforms applied to both human and veterinary pharmaceutical development. These platforms enable the company to create and mass-produce innovative drug delivery systems, which are critical for the efficacy of their medicine portfolios. Revenue streams are derived from direct sales of these medicines to healthcare providers and veterinary institutions within their target markets. Inventage Lab, Inc. operates with a dual focus on human and veterinary pharmaceuticals, utilizing its specialized platforms to address unmet medical needs in both sectors. The company's product range includes treatments for specific conditions like male pattern baldness and prostate cancer, alongside veterinary applications such as chemical castration agents, which are sold to relevant industry stakeholders in their respective markets. Inventage Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Inventage Lab stock

EBITDA per Share of Inventage Lab is -2,137.56 KRW in 2025.

EBITDA per Share of Inventage Lab changed from -1,706.45 KRW to -2,137.56 KRW, representing a 25.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Inventage Lab since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Inventage Lab

All Key Metrics — Inventage Lab